1
|
Malanina A, Kuzin Y, Khadieva A, Shibaeva K, Padnya P, Stoikov I, Evtugyn G. Voltammetric Sensor for Doxorubicin Determination Based on Self-Assembled DNA-Polyphenothiazine Composite. NANOMATERIALS (BASEL, SWITZERLAND) 2023; 13:2369. [PMID: 37630955 PMCID: PMC10459114 DOI: 10.3390/nano13162369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Revised: 08/11/2023] [Accepted: 08/12/2023] [Indexed: 08/27/2023]
Abstract
A novel voltammetric sensor based on a self-assembled composite formed by native DNA and electropolymerized N-phenyl-3-(phenylimino)-3H-phenothiazin-7-amine has been developed and applied for sensitive determination of doxorubicin, an anthracycline drug applied for cancer therapy. For this purpose, a monomeric phenothiazine derivative has been deposited on the glassy carbon electrode from the 0.4 M H2SO4-acetone mixture (1:1 v/v) by multiple potential cycling. The DNA aliquot was either on the electrode modified with electropolymerized film or added to the reaction medium prior to electropolymerization. The DNA entrapment and its influence on the redox behavior of the underlying layer were studied by scanning electron microscopy and electrochemical impedance spectroscopy. The DNA-doxorubicin interactions affected the charge distribution in the surface layer and, hence, altered the redox equilibrium of the polyphenothiazine coating. The voltametric signal was successfully applied for the determination of doxorubicin in the concentration range from 10 pM to 0.2 mM (limit of detection 5 pM). The DNA sensor was tested on spiked artificial plasma samples and two commercial medications (recovery of 90-95%). After further testing on real clinical samples, the electrochemical DNA sensor developed can find application in monitoring drug release and screening new antitumor drugs able to intercalate DNA.
Collapse
Affiliation(s)
- Anastasiya Malanina
- A.M. Butlerov Chemistry Institute, Kazan Federal University, 18 Kremlevskaya Street, Kazan 420008, Russia
| | - Yurii Kuzin
- A.M. Butlerov Chemistry Institute, Kazan Federal University, 18 Kremlevskaya Street, Kazan 420008, Russia
| | - Alena Khadieva
- A.M. Butlerov Chemistry Institute, Kazan Federal University, 18 Kremlevskaya Street, Kazan 420008, Russia
| | - Kseniya Shibaeva
- A.M. Butlerov Chemistry Institute, Kazan Federal University, 18 Kremlevskaya Street, Kazan 420008, Russia
| | - Pavel Padnya
- A.M. Butlerov Chemistry Institute, Kazan Federal University, 18 Kremlevskaya Street, Kazan 420008, Russia
| | - Ivan Stoikov
- A.M. Butlerov Chemistry Institute, Kazan Federal University, 18 Kremlevskaya Street, Kazan 420008, Russia
| | - Gennady Evtugyn
- A.M. Butlerov Chemistry Institute, Kazan Federal University, 18 Kremlevskaya Street, Kazan 420008, Russia
- Analytical Chemistry Department, Chemical Technology Institute, Ural Federal University, 19 Mira Street, Ekaterinburg 620002, Russia
| |
Collapse
|
2
|
Sousa DVM, Pereira FV, Boratto VHM, Orlando RM. Multiphase electroextraction as a simple and fast sample preparation alternative for the digital image determination of doxorubicin in saliva. Talanta 2023; 255:124242. [PMID: 36638654 DOI: 10.1016/j.talanta.2022.124242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2022] [Revised: 12/27/2022] [Accepted: 12/29/2022] [Indexed: 01/01/2023]
Abstract
Monitoring chemotherapeutic drugs in biological fluids is, in many cases, extremely important for dose adjustment, the maintenance of therapies, and the control of side effects. In this work, a method for determining the doxorubicin in saliva by digital image analysis (DIA) was optimised and validated. Images from a paper point were obtained using a conventional and cheap flatbed scanner at a 600 ppp resolution. The RGB data channels were obtained from the images in a region of 15 × 15 pixels around the sorbent vertex. The paper point was used as sorbent material in sample preparation using a multiphase electroextraction system. Following optimisation using a Doehlert experimental design, the method was able to simultaneously extract 66 samples in 20 min. The high selectivity of the electric field associated with the sorption capacity of the cellulosic material allowed the chemotherapy drug to be pre-concentrated and quantified in a range between 50 and 500 μg L-1 (R2 > 0.98). The method also exhibited adequate parameters (limits of detection and quantification, recovery, and precision) indicating its potential application in the monitoring of doxorubicin and similar drugs in saliva.
Collapse
|
3
|
Determination of the effect of berberine on epirubicin concentration in MCF-7 cells by LC-MS/MS: the mechanism of synergism explained by intracellular pharmacokinetics. J Pharm Biomed Anal 2022; 214:114692. [DOI: 10.1016/j.jpba.2022.114692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Revised: 01/26/2022] [Accepted: 02/24/2022] [Indexed: 11/18/2022]
|
4
|
A highly sensitive UHPLC-MS/MS method for urine biological monitoring of occupational exposure to anthracycline antineoplastic drugs and routine application. J Chromatogr B Analyt Technol Biomed Life Sci 2020; 1156:122305. [DOI: 10.1016/j.jchromb.2020.122305] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Revised: 07/30/2020] [Accepted: 08/04/2020] [Indexed: 01/25/2023]
|
5
|
Menz BD, Stocker SL, Verougstraete N, Kocic D, Galettis P, Stove CP, Reuter SE. Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology. Br J Clin Pharmacol 2020; 87:227-236. [PMID: 32430968 DOI: 10.1111/bcp.14372] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Revised: 04/29/2020] [Accepted: 04/30/2020] [Indexed: 12/12/2022] Open
Abstract
There are few fields of medicine in which the individualisation of medicines is more important than in the area of oncology. Under-dosing can have significant ramifications due to the potential for therapeutic failure and cancer progression; by contrast, over-dosing may lead to severe treatment-limiting side effects, such as agranulocytosis and neutropenia. Both circumstances lead to poor patient prognosis and contribute to the high mortality rates still seen in oncology. The concept of dose individualisation tailors dosing for each individual patient to ensure optimal drug exposure and best clinical outcomes. While the value of this strategy is well recognised, it has seen little translation to clinical application. However, it is important to recognise that the clinical setting of oncology is unlike that for which therapeutic drug monitoring (TDM) is currently the cornerstone of therapy (e.g. antimicrobials). Whilst there is much to learn from these established TDM settings, the challenges presented in the treatment of cancer must be considered to ensure the implementation of TDM in clinical practice. Recent advancements in a range of scientific disciplines have the capacity to address the current system limitations and significantly enhance the use of anticancer medicines to improve patient health. This review examines opportunities presented by these innovative scientific methodologies, specifically sampling strategies, bioanalytics and dosing decision support, to enable optimal practice and facilitate the clinical implementation of TDM in oncology.
Collapse
Affiliation(s)
- Bradley D Menz
- SA Pharmacy, Flinders Medical Centre, Adelaide, SA, Australia
| | - Sophie L Stocker
- Department of Clinical Pharmacology & Toxicology, St Vincent's Hospital, Sydney, NSW, Australia.,St. Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia
| | - Nick Verougstraete
- Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium.,Laboratory of Toxicology, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
| | - Danijela Kocic
- Department of Clinical Pharmacology & Toxicology, St Vincent's Hospital, Sydney, NSW, Australia.,St. Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia
| | - Peter Galettis
- Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, Australia
| | - Christophe P Stove
- Laboratory of Toxicology, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
| | - Stephanie E Reuter
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA, Australia
| |
Collapse
|
6
|
Šimek M, Hermannová M, Šmejkalová D, Foglová T, Souček K, Binó L, Velebný V. LC–MS/MS study of in vivo fate of hyaluronan polymeric micelles carrying doxorubicin. Carbohydr Polym 2019; 209:181-189. [DOI: 10.1016/j.carbpol.2018.12.104] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Revised: 12/13/2018] [Accepted: 12/27/2018] [Indexed: 11/28/2022]
|
7
|
Arkan E, Paimard G, Moradi K. A novel electrochemical sensor based on electrospun TiO 2 nanoparticles/carbon nanofibers for determination of Idarubicin in biological samples. J Electroanal Chem (Lausanne) 2017. [DOI: 10.1016/j.jelechem.2017.08.034] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Mazzucchelli S, Ravelli A, Gigli F, Minoli M, Corsi F, Ciuffreda P, Ottria R. LC-MS/MS method development for quantification of doxorubicin and its metabolite 13-hydroxy doxorubicin in mice biological matrices: Application to a pharmaco-delivery study. Biomed Chromatogr 2016; 31. [PMID: 27714830 DOI: 10.1002/bmc.3863] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Revised: 09/28/2016] [Accepted: 10/04/2016] [Indexed: 11/08/2022]
Abstract
This study describes the development of simple, rapid and sensitive liquid chromatography tandem mass spectrometry method for the simultaneous analysis of doxorubicin and its major metabolite, doxorubicinol, in mouse plasma, urine and tissues. The calibration curves were linear over the range 5-250 ng/mL for doxorubicin and 1.25-25 ng/mL for doxorubicinol in plasma and tumor, over the range 25-500 ng/mL for doxorubicin and 1.25-25 ng/mL for doxorubicinol in liver and kidney, and over the range 25-1000 ng/mL for doxorubicin and doxorubicinol in urine. The study was validated, using quality control samples prepared in all different matrices, for accuracy, precision, linearity, selectivity, lower limit of quantification and recovery in accordance with the US Food & Drug Administration guidelines. The method was successfully applied in determining the pharmaco-distribution of doxorubicin and doxorubicinol after intravenously administration in tumor-bearing mice of drug, free or nano-formulated in ferritin nanoparticles or in liposomes. Obtained results demonstrate an effective different distribution and doxorubicin protection against metabolism linked to nano-formulation. This method, thanks to its validation in plasma and urine, could be a powerful tool for pharmaceutical research and therapeutic drug monitoring, which is a clinical approach currently used in the optimization of oncologic treatments.
Collapse
Affiliation(s)
- Serena Mazzucchelli
- Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco", Università degli Studi di Milano, Italy
| | - Alessandro Ravelli
- Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Sezione di Tossicologia Forense, Università degli Studi di Milano, Italy
| | - Fausto Gigli
- Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Sezione di Tossicologia Forense, Università degli Studi di Milano, Italy
| | - Mauro Minoli
- Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Sezione di Tossicologia Forense, Università degli Studi di Milano, Italy
| | - Fabio Corsi
- Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco", Università degli Studi di Milano, Italy
| | - Pierangela Ciuffreda
- Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco", Università degli Studi di Milano, Italy
| | - Roberta Ottria
- Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco", Università degli Studi di Milano, Italy
| |
Collapse
|
9
|
Wohlfarth A, Scheidweiler KB, Pang S, Zhu M, Castaneto M, Kronstrand R, Huestis MA. Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation. Drug Test Anal 2016; 8:779-91. [PMID: 26331297 PMCID: PMC4562414 DOI: 10.1002/dta.1856] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2015] [Revised: 07/14/2015] [Accepted: 07/14/2015] [Indexed: 11/11/2022]
Abstract
AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) is a new synthetic opioid and has led to multiple non-fatal and fatal intoxications. To comprehensively study AH-7921 metabolism, we assessed human liver microsome (HLM) metabolic stability, determined AH-7921's metabolic profile after human hepatocytes incubation, confirmed our findings in a urine case specimen, and compared results to in silico predictions. For metabolic stability, 1 µmol/L AH-7921 was incubated with HLM for up to 1 h; for metabolite profiling, 10 µmol/L was incubated with pooled human hepatocytes for up to 3 h. Hepatocyte samples were analyzed by liquid chromatography quadrupole/time-of-flight high-resolution mass spectrometry (MS). High-resolution full scan MS and information-dependent acquisition MS/MS data were analyzed with MetabolitePilot™ (SCIEX) using multiple data processing algorithms. The presence of AH-7921 and metabolites was confirmed in the urine case specimen. In silico prediction of metabolite structures was performed with MetaSite™ (Molecular Discovery). AH-7921 in vitro half-life was 13.5 ± 0.4 min. We identified 12 AH-7921 metabolites after hepatocyte incubation, predominantly generated by demethylation, less dominantly by hydroxylation, and combinations of different biotransformations. Eleven of 12 metabolites identified in hepatocytes were found in the urine case specimen. One metabolite, proposed to be di-demethylated, N-hydroxylated and glucuronidated, eluted after AH-7921 and was the most abundant metabolite in non-hydrolyzed urine. MetaSite™ correctly predicted the two most abundant metabolites and the majority of observed biotransformations. The two most dominant metabolites after hepatocyte incubation (also identified in the urine case specimen) were desmethyl and di-desmethyl AH-7921. Together with the glucuronidated metabolites, these are likely suitable analytical targets for documenting AH-7921 intake. Copyright © 2015 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Ariane Wohlfarth
- Chemistry and Drug Metabolism, Intramural Research Program, National
Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224,
USA
| | - Karl B. Scheidweiler
- Chemistry and Drug Metabolism, Intramural Research Program, National
Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224,
USA
| | | | - Mingshe Zhu
- Department of Biotransformation, Bristol-Myers Squibb Research and
Development, Princeton, NJ 08543, USA
| | - Marisol Castaneto
- Chemistry and Drug Metabolism, Intramural Research Program, National
Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224,
USA
| | - Robert Kronstrand
- Department of Forensic Genetics and Forensic Toxicology, National
Board of Forensic Medicine, 58758 Linköping, Sweden
- Department of Drug Research, University of Linköping, 58185
Linköping, Sweden
| | - Marilyn A. Huestis
- Chemistry and Drug Metabolism, Intramural Research Program, National
Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224,
USA
| |
Collapse
|
10
|
Hajian R, Tayebi Z, Shams N. Fabrication of an electrochemical sensor for determination of doxorubicin in human plasma and its interaction with DNA. J Pharm Anal 2016; 7:27-33. [PMID: 29404015 PMCID: PMC5686857 DOI: 10.1016/j.jpha.2016.07.005] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Revised: 07/10/2016] [Accepted: 07/16/2016] [Indexed: 11/02/2022] Open
Abstract
In this work, an electrochemical sensor was fabricated for determination of an anthracycline, doxorubicin (DOX) as a chemotherapy drug in plasma based on multi-walled carbon nanotubes modified platinum electrode (Pt/MWCNTs). DOX was effectively accumulated on the surface of modified electrode and generated a pair of redox peaks at around 0.522 and 0.647 V (vs. Ag/AgCl) in Britton Robinson (B-R) buffer (pH 4.0, 0.1 M). The electrochemical parameters including pH, type of buffer, accumulation time, amount of modifier and scan rate were optimized. Under the optimized conditions, there was a linear correlation between cathodic peak current and concentration of DOX in the range of 0.05-4.0 µg/mL with the detection limit of 0.002 µg/mL. The number of electron transfers (n) and electron transfer-coefficient (α) were estimated as 2.0 and 0.25, respectively. The constructed sensor displayed excellent precision, sensitivity, repeatability and selectivity in the determination of doxorubicin in plasma. Moreover, cyclic voltammetry studies of DOX in the presence of DNA showed an intercalation mechanism with binding constant (Kb) of 1.12×105 L/mol.
Collapse
Affiliation(s)
- Reza Hajian
- Young Researchers and Elite Club, Gachsaran Branch, Islamic Azad University, 75818-63876 Gachsaran, Iran
| | - Zahra Tayebi
- Department of Chemistry, College of Science, Gachsaran Branch, Islamic Azad University, 75818-63876 Gachsaran, Iran
| | - Nafiseh Shams
- Institute of Advanced Technology, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia
| |
Collapse
|
11
|
KOZIOLOVA E, JANOUSKOVA O, CHYTIL P, STUDENOVSKY M, KOSTKA L, ETRYCH T. Nanotherapeutics With Anthracyclines: Methods of Determination and Quantification of Anthracyclines in Biological Samples. Physiol Res 2015; 64:S1-10. [DOI: 10.33549/physiolres.933140] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Anthracyclines, e.g. doxorubicin, pirarubicin, are widely used as cytostatic agents in the polymer nanotherapeutics designed for the highly effective antitumor therapy with reduced side effects. However, their precise dosage scheme needs to be optimized, which requires an accurate method for their quantification on the cellular level in vitro during nanocarrier development and in body fluids and tissues during testing in vivo. Various methods detecting the anthracycline content in biological samples have already been designed. Most of them are highly demanding and they differ in exactness and reproducibility. The cellular uptake and localization is predominantly observed and determined by microscopy techniques, the anthracycline content is usually quantified by chromatographic analysis using fluorescence detection. We reviewed and compared published methods concerning the detection of anthracycline nanocarriers.
Collapse
Affiliation(s)
- E. KOZIOLOVA
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | | | | | | | | | | |
Collapse
|
12
|
Evtugyn G, Porfireva A, Stepanova V, Budnikov H. Electrochemical Biosensors Based on Native DNA and Nanosized Mediator for the Detection of Anthracycline Preparations. ELECTROANAL 2015. [DOI: 10.1002/elan.201400564] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
13
|
Pérez-Blanco JS, Fernández de Gatta MDM, Hernández-Rivas JM, García Sánchez MJ, Sayalero Marinero ML, González López F. Validation and clinical evaluation of a UHPLC method with fluorescence detector for plasma quantification of doxorubicin and doxorubicinol in haematological patients. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 955-956:93-7. [PMID: 24631816 DOI: 10.1016/j.jchromb.2014.02.034] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2013] [Revised: 01/30/2014] [Accepted: 02/17/2014] [Indexed: 11/18/2022]
Abstract
A rapid and simple UHPLC-fluorescence detection method for the quantification of doxorubicin and its main metabolite, doxorubicinol, in human plasma has been developed. The method was also validated for its application in therapeutic drug monitoring, a clinical approach used in the optimization of oncologic treatments. Following a single protein precipitation step, chromatographic separation was achieved using a C18 column (50mm×2.10mm, particle size 1.7μm) at 50°C with a mobile phase consisting of water (containing 0.4% triethylamine and 0.4% orthophosphoric acid)/acetonitrile (77:23, v/v). Flow rate was 0.50mL/min and fluorescence detection with an excitation wavelength of 470nm and an emission wavelength of 548nm was used. The method met the specifications of linearity, selectivity, sensitivity, accuracy, precision and stability of the FDA and EMA guidelines for the validation of bioanalytical methods. Linearity for the drug (8-3000ng/mL) and the metabolite (3-150ng/mL) was observed (R(2)>0.992) and the maximum intra-day and inter-day precision coefficients of variation were less than 14% for both. The lower limits of quantification were 8 and 3ng/mL for doxorubicin and doxorubicinol, respectively. The method was successfully applied to the quantify plasma concentrations of doxorubicin and doxorubicinol in 33 patients diagnosed with haematological malignancies in which broad ranges for drug (8.3-2766.0ng/mL) and metabolite (4.8-104.9ng/mL) levels were measured adequately.
Collapse
Affiliation(s)
- Jonás Samuel Pérez-Blanco
- Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Salamanca, Avda Lcdo Méndez Nieto s/n, 37007 Salamanca, Spain; Salamanca Institute for Biomedical Research (IBSAL), University Hospital of Salamanca, Paseo San Vicente 58-182, 37007 Salamanca, Spain.
| | - María del Mar Fernández de Gatta
- Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Salamanca, Avda Lcdo Méndez Nieto s/n, 37007 Salamanca, Spain; Salamanca Institute for Biomedical Research (IBSAL), University Hospital of Salamanca, Paseo San Vicente 58-182, 37007 Salamanca, Spain
| | - Jesús María Hernández-Rivas
- Haematology Service, University Hospital of Salamanca and IBMCC, Cancer Research Center, University of Salamanca-CSIC, Campus Miguel de Unamuno, 37007 Salamanca, Spain; Salamanca Institute for Biomedical Research (IBSAL), University Hospital of Salamanca, Paseo San Vicente 58-182, 37007 Salamanca, Spain
| | - María José García Sánchez
- Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Salamanca, Avda Lcdo Méndez Nieto s/n, 37007 Salamanca, Spain; Salamanca Institute for Biomedical Research (IBSAL), University Hospital of Salamanca, Paseo San Vicente 58-182, 37007 Salamanca, Spain
| | - María Luisa Sayalero Marinero
- Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Salamanca, Avda Lcdo Méndez Nieto s/n, 37007 Salamanca, Spain; Salamanca Institute for Biomedical Research (IBSAL), University Hospital of Salamanca, Paseo San Vicente 58-182, 37007 Salamanca, Spain
| | - Francisco González López
- Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Salamanca, Avda Lcdo Méndez Nieto s/n, 37007 Salamanca, Spain
| |
Collapse
|
14
|
|